Skin cancer is the most common cancer in the United States, affecting approximately 1 in 5 Americans during their lifetime, according to the Skin Cancer Foundation. It is also one of the most preventable and, when caught early, one of the most treatable. This guide explains the three main types of skin cancer, how ultraviolet (UV) exposure damages skin at the cellular level, who faces the highest risk, and how modern treatments like Mohs micrographic surgery and, for early lesions, photodynamic therapy work — so you can recognize warning signs early and protect yourself.
- Who Is Most at Risk for Skin Cancer
- The Three Main Types of Skin Cancer
- How Sun Exposure Causes Skin Cancer: The UV Mechanism
- Skin Cancer Treatment and Mohs Surgery Explained
Who Is Most at Risk for Skin Cancer
Skin cancer risk rises with cumulative lifetime UV exposure, so the people most affected tend to be those who spend years in high-UV environments. The American Academy of Dermatology (AAD) identifies key risk factors including fair skin that burns easily, a history of sunburns or indoor tanning, extensive outdoor work or recreation, a family or personal history of skin cancer, and a large number of moles or atypical (dysplastic) moles. Outdoor athletes and people who work under intense lighting or sun for years accumulate a UV dose far higher than the average indoor worker, which is why occupational and recreational sun exposure are central to prevention guidance.
Why Athletes and Entertainers Face Higher Risk
Professional athletes frequently train outdoors for extended hours, accumulating UV dose that most office-based individuals do not. The IARC classifies solar UV radiation as a Group 1 carcinogen — the highest category of confirmed human carcinogens. Repeated UV exposure triggers cyclobutane pyrimidine dimer (CPD) DNA damage in keratinocytes, the primary cell type of the epidermis. Studies suggest that individuals with fair skin on the Fitzpatrick skin type scale (Types I–II) face the highest cumulative risk. The key takeaway is that no level of fitness, youth, or outdoor experience protects against UV-driven cellular damage — consistent sun protection is what reduces risk.
The Three Main Types of Skin Cancer
Basal Cell Carcinoma (BCC)
BCC is the most common form of skin cancer, accounting for approximately 80% of cases, according to the Skin Cancer Foundation. It originates in basal cells at the deepest layer of the epidermis. BCC rarely metastasizes to distant sites, but it can cause significant local tissue destruction if left untreated for extended periods. Mohs surgery achieves cure rates exceeding 99% for primary BCC lesions, making early diagnosis the most important factor in a favorable outcome. Many celebrities with skin cancer who speak publicly have been treated for BCC.
Squamous Cell Carcinoma (SCC) and Actinic Keratosis
SCC arises from squamous keratinocytes and accounts for roughly 20% of skin cancer diagnoses. It carries a higher metastatic potential than BCC. A precursor condition called actinic keratosis — rough, scaly patches caused by UV-damaged skin cells — can progress to invasive SCC in approximately 5–10% of untreated cases, according to AAD estimates. Early dermatological evaluation and treatment of actinic keratosis substantially reduces that progression risk and is a standard recommendation from the American Academy of Dermatology.
Melanoma
Melanoma originates in melanocytes and is the most aggressive form of skin cancer. The SEER program estimates approximately 100,000 new melanoma diagnoses annually in the United States. Dermoscopy — a non-invasive imaging technique used by dermatologists — aids early detection and significantly improves staging accuracy under the AJCC TNM classification system. When melanoma is caught at Stage I under TNM staging, SEER data suggest five-year survival rates exceed 98%, underscoring the critical value of annual skin exams.
How Sun Exposure Causes Skin Cancer: The UV Mechanism
UV radiation, classified by IARC as a Group 1 carcinogen, is the primary environmental driver of skin cancer, responsible for more than 90% of non-melanoma skin cancers. Understanding how UV rays damage DNA explains why early and consistent sun protection matters throughout a person’s lifetime.
UVA vs. UVB Damage at the Cellular Level
UVA rays (320–400 nm) penetrate deep into the dermis and generate reactive oxygen species that cause indirect DNA strand breaks. UVB rays (280–320 nm) directly induce cyclobutane pyrimidine dimers (CPDs) in the DNA of epidermal keratinocytes. CPD formation disrupts the tumor suppressor gene TP53, a mutation documented in more than 50% of SCC tumors. When DNA repair mechanisms — including nucleotide excision repair — are overwhelmed or genetically defective, as seen in xeroderma pigmentosum, malignant transformation accelerates toward skin cancer melanoma or non-melanoma pathways.
Cumulative Dose and Fitzpatrick Skin Typing
Skin cancer risk correlates directly with cumulative lifetime UV dose. The Fitzpatrick skin type scale ranks phototypes from Type I (very fair, always burns, never tans) to Type VI (deeply pigmented, rarely burns). Individuals rated Type I or II face substantially higher lifetime risk than Types V–VI. The Skin Cancer Foundation recommends broad-spectrum SPF 30 or higher daily, with published clinical trial data suggesting consistent use reduces SCC risk by approximately 40%.
Skin Cancer Treatment and Mohs Surgery Explained
Treatment selection for skin cancer depends on type, location, size, and staging under the AJCC TNM classification. Physicians at centers such as MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center routinely treat complex skin cancer cases using a range of evidence-based approaches.
Mohs Micrographic Surgery
Mohs surgery is the gold-standard procedure for high-risk BCC and SCC on cosmetically sensitive or functionally critical sites such as the face, ears, and hands. A Mohs surgeon removes tissue in successive thin layers, examining each layer under microscopy in real time until clear margins are confirmed. The Skin Cancer Foundation reports cure rates of 98–99% for primary tumors treated with Mohs. The technique minimizes removal of healthy surrounding tissue, making it particularly valuable for lesions in visible facial areas where tissue preservation is essential.
Systemic and Advanced Treatment Options
For early-stage melanoma, wide local excision combined with sentinel lymph node biopsy guides AJCC TNM staging. Advanced melanoma may require targeted therapy — such as BRAF inhibitors (vemurafenib, dabrafenib) for BRAF V600E-mutated tumors — or immunotherapy agents including pembrolizumab or nivolumab, both FDA-approved checkpoint inhibitors. Radiation therapy, topical agents such as imiquimod or 5-fluorouracil, and photodynamic therapy provide additional options for superficial lesions, as evaluated by the treating oncology team at the patient’s cancer center.
Frequently Asked Questions
How common is skin cancer?
Skin cancer is the most common cancer in the United States. The Skin Cancer Foundation estimates that approximately 9,500 Americans are diagnosed with skin cancer every day, and that 1 in 5 Americans will develop skin cancer by age 70. The good news is that when detected early, the five-year survival rate for melanoma is 99 percent, and non-melanoma skin cancers such as basal cell and squamous cell carcinoma are highly treatable. Regular skin self-exams and annual dermatologist checkups are the most effective ways to catch it early.
What is actinic keratosis and is it dangerous?
Actinic keratosis (AK) is a rough, scaly patch on the skin caused by cumulative sun exposure over many years. The American Academy of Dermatology classifies AK as a precancerous condition because approximately 5–10% of untreated lesions can progress to squamous cell carcinoma. AK most commonly appears on sun-exposed areas — the scalp, face, ears, hands, and forearms. It is most frequent in people over 40 with fair skin and significant lifetime UV exposure. Dermatologists treat AK with cryotherapy using liquid nitrogen, topical agents such as 5-fluorouracil, or photodynamic therapy. Early treatment significantly reduces the risk of progression to invasive skin cancer.
What SPF should you use to help prevent skin cancer?
The Skin Cancer Foundation and the American Academy of Dermatology recommend a broad-spectrum sunscreen with SPF 30 or higher for daily use. SPF 30 blocks approximately 97% of UVB rays, while SPF 50 blocks approximately 98%. No sunscreen blocks 100% of UV radiation, so reapplication every two hours — or immediately after swimming or sweating — is essential. Broad-spectrum formulas protect against both UVA and UVB damage. Published clinical trial data suggest consistent daily SPF use reduces squamous cell carcinoma risk by approximately 40%. Combining sunscreen with protective clothing, wide-brim hats, and avoidance of peak UV hours between 10 a.m. and 4 p.m. provides the strongest prevention strategy.
Key Takeaways
- Skin cancer is the most common cancer in the U.S., and cumulative UV exposure is its leading cause — outdoor athletes and workers face elevated risk.
- IARC classifies UV radiation as a Group 1 carcinogen, driving more than 90% of non-melanoma skin cancers through CPD DNA damage in keratinocytes.
- BCC, SCC, and melanoma are the three primary types; actinic keratosis is a common precancer that can progress to invasive SCC in 5–10% of untreated cases.
- Mohs surgery achieves cure rates of 98–99% for primary BCC and SCC lesions, with real-time microscopy confirming clear margins.
- Daily broad-spectrum SPF 30 reduces SCC risk by approximately 40%, according to published clinical trial data from the Skin Cancer Foundation.